Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress

被引:147
|
作者
Milne, Ginger L. [1 ]
Yin, Huiyong [1 ]
Brooks, Joshua D. [1 ]
Sanchez, Stephanie [1 ]
Roberts, L. Jackson, II [1 ]
Morrow, Jason D. [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA
关键词
D O I
10.1016/S0076-6879(07)33006-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Oxidant stress has been implicated in a wide variety of disease processes. One method to quantify oxidative injury is to measure lipid peroxidation. Quantification of a group of prostaglandin F-2-like compounds derived from the nonezymatic oxidation of arachidonic acid, termed the F-2-isoprostanes (F-2-IsoPs), provides an accurate assessment of oxidative stress both in vitro and in vivo. In fact, in a recent National Institutes of Health-sponsored independent study, F2-IsoPs were shown to be the most reliable index of in vivo oxidant stress when compared against other well-known biomarkers. This article summarizes current methodology used to quantify these molecules. Our laboratory's method to measure F2-IsoPs in biological fluids and tissues using gas chromatography-mass spectrometry is detailed herein. In addition, other mass spectrometric approaches, as well as immunological methods to measure these compounds, are discussed. Finally, the utility of these molecules as in vivo biomarkers of oxidative stress is summarized.
引用
收藏
页码:113 / 126
页数:14
相关论文
共 50 条
  • [31] Prolonged exercise, lymphocyte apoptosis and F2-isoprostanes
    Steensberg, A
    Morrow, J
    Toft, AD
    Bruunsgaard, H
    Pedersen, BK
    EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2002, 87 (01) : 38 - 42
  • [32] Prolonged exercise, lymphocyte apoptosis and F2-isoprostanes
    Adam Steensberg
    Jason Morrow
    Anders Toft
    Helle Bruunsgaard
    Bente Pedersen
    European Journal of Applied Physiology, 2002, 87 : 38 - 42
  • [33] F2-isoprostanes in Alzheimer and other neurodegenerative diseases
    Montine, TJ
    Montine, KS
    McMahan, W
    Markesbery, WR
    Quinn, JF
    Morrow, JD
    ANTIOXIDANTS & REDOX SIGNALING, 2005, 7 (1-2) : 269 - 275
  • [34] Biomarkers of Alzheimer's disease: F2-isoprostanes
    Pratico, D
    NEUROBIOLOGY OF AGING, 2004, 25 : S5 - S5
  • [35] IDENTIFICATION AND CHARACTERIZATION OF NOVEL METABOLITES OF F2-ISOPROSTANES
    Nogueira, Marina
    Sanchez, Stephanie
    Gao, Benlian
    Amin, Warda
    Thomas, Sarah
    Yang, Gong
    Milne, Ginger
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [36] Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans
    Morrow, JD
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (02) : 279 - 286
  • [37] From Biomarker to Mechanism? F2-isoprostanes in Pulmonary Fibrosis
    Thatcher, Thomas H.
    Peters-Golden, Marc
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 206 (05) : 530 - 532
  • [38] Effects of F2-isoprostanes on endothelial dysfunction in an experimental hypercholesterolemia
    Ishizuka, T
    Matsui, T
    Takase, B
    Satomura, K
    Kurita, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 288A - 289A
  • [39] Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation
    Vanharanta, M
    Voutilainen, S
    Nurmi, T
    Kaikkonen, J
    Roberts, LJ
    Morrow, JD
    Adlercreutz, H
    Salonen, JT
    ATHEROSCLEROSIS, 2002, 160 (02) : 465 - 469
  • [40] Association of dietary and plasma carotenoids with urinary F2-isoprostanes
    Park, Yong-Moon Mark
    Lilyquist, Jenna
    Erve, Thomas J. Van't
    O'Brien, Katie M.
    Nichols, Hazel B.
    Milne, Ginger L.
    Weinberg, Clarice R.
    Sandler, Dale P.
    EUROPEAN JOURNAL OF NUTRITION, 2022, 61 (05) : 2711 - 2723